Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > KRAS


Brief Information

Name:V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
Target Synonym:KRAS,V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:17
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

KRAS MALS images

The purity of Human KRAS (2-185,G12D), His Tag (Cat. No. KRS-H51H4) is more than 90% and the molecular weight of this protein is around 24-34 kDa verified by SEC-MALS.

Synonym Name



KRAS (Kirsten rat sarcoma 2 viral oncogene homolog) gene is a proto-oncogene that encodes a small GTPase transductor protein called KRAS. KRAS is also known as Ki-Ras, c-K-ras andc-Ki-ras. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Plays an important role in the regulation of cell proliferation, promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner. RAS is one of the most frequently mutated oncogenes in human cancer but the frequency and distribution of RAS gene mutations are not uniform. In details, mutation of glycine 12 (G12) causes RAS activation by interfering with GAP binding and GAP-stimulated GTP hydrolysis. The reference shows the pathway may as a potential therapy targets.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ZG-2001 ZG2001; ZG-2001 Phase 2 Clinical Suzhou Zelgen Biopharmaceuticals Co Ltd Solid tumours; Neoplasms Details
ELI-002 Amph-CpG-7909; ELI-002; ELI-002 2P; VED-002 Phase 2 Clinical Elicio Therapeutics Ovarian Neoplasms; Solid tumours; Neoplasm, Residual; Cholangiocarcinoma; Colorectal Neoplasms; Bile Duct Neoplasms; Gallbladder Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung Details
Pooled mutant-KRAS peptide vaccine (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins) Phase 1 Clinical Sidney Kimmel Comprehensive Cancer Center Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
mRNA-5671 mRNA-5671 Phase 1 Clinical Moderna Inc, Merck & Co Inc Pancreatic Neoplasms; Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
mDC3/8-KRAS Vaccine (University of Pennsylvania) Phase 1 Clinical University Of Pennsylvania Carcinoma, Pancreatic Ductal Details
BI-3706674 BI-3706674; BI3706674; BI 3706674 Phase 1 Clinical C.H. Boehringer Sohn Ag & Co. Kg Solid tumours; Stomach Neoplasms; Esophageal Neoplasms Details
YL-17231 YL-17231; YL17231; TEB-17231 Phase 1 Clinical YL-Pharma Solid tumours; Neoplasms Details
QTX-3034 QTX3034; QTX-3034 Phase 1 Clinical Quanta Therapeutics Inc Solid tumours; Neoplasms Details
RNA tumor vaccine (First Affiliated Hospital Bengbu Medical College) Phase 1 Clinical First Affiliated Hospital Bengbu Medical College Solid tumours Details
RMC-9805 RM-036; RMC-9805 Phase 1 Clinical Revolution Medicines Inc Solid tumours; Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung Details
LUNA-18 LUNA-18 Phase 1 Clinical Chugai Pharmaceutical Co Ltd Solid tumours Details
BEBT-607 C200825009-FP; BEBT-607 Phase 1 Clinical Guangzhou BeBetter Medicine Technology Co Solid tumours; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
BI-1701963 BI-1701963 Phase 1 Clinical Forma Therapeutics Holdings Inc Solid tumours; Colorectal Neoplasms Details
CWG-59r CWG-59r; CWG-59-r; CWG59r Clinical Cellworks Group Neoplasms Details
CWG-71b CWG-71b; CWG-71-b; CWG71b Clinical Cellworks Group Neoplasms Details
CWG-89 CWG-89 Clinical Cellworks Group Neoplasms Details
CWG-71a (Cellworks Group) CWG-71a Clinical Cellworks Group Inc Neoplasms Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message